Jardiance Adolescent (12 to 17) Dosing: What Clinicians and Parents Should Know

FDA Approval and Regulatory Background

The FDA expanded the empagliflozin label to include pediatric patients aged 10 and older with type 2 diabetes in June 2023, making Jardiance one of only a few non-insulin, non-metformin options cleared for this age group. The approval was based on the DINAMO trial, a 26-week, double-blind, placebo-controlled study that enrolled children and adolescents with type 2 diabetes across multiple countries [1].

The DINAMO Trial Design

DINAMO (NCT03429543) randomized 158 patients aged 10 to 17 to empagliflozin 10 mg, empagliflozin 25 mg, linagliptin 5 mg, or placebo. The primary endpoint was change in HbA1c from baseline at week 26. Participants had a mean baseline HbA1c of approximately 7.9%, and most were already receiving metformin, insulin, or both [2].

Efficacy Outcomes in Teens

The empagliflozin arms showed a placebo-adjusted HbA1c reduction of roughly 0.2%, a modest but statistically meaningful difference given the small sample size and high placebo response. Body weight decreased by approximately 2.5 kg relative to placebo in the 25 mg group, a secondary outcome that carries practical significance for adolescents with obesity-driven type 2 diabetes [2]. The American Diabetes Association (ADA) Standards of Care 2024 now lists SGLT2 inhibitors as a pharmacologic option for youth with type 2 diabetes when metformin alone is insufficient [3].

Dosing Protocol for Adolescents (12 to 17)

Empagliflozin dosing in adolescents mirrors the adult regimen. The starting dose is 10 mg taken once daily in the morning, with or without food. If glycemic targets are not met after 4 to 8 weeks and the patient tolerates the medication, the prescriber may increase to 25 mg once daily [4].

No Weight-Based Adjustment

Unlike many pediatric medications, empagliflozin is not dosed by weight. The pharmacokinetic profile in adolescents weighing 40 kg or more closely matches adult exposure, which supported the FDA's decision to use fixed dosing rather than mg/kg calculations [4]. For adolescents weighing less than 40 kg, data remain limited, and clinicians should weigh the risk-benefit ratio on a case-by-case basis.

Timing and Administration

The tablet should be swallowed whole. No scored or crushable formulation exists, and no oral solution is commercially available. For teens who struggle with pill swallowing, a brief behavioral training protocol (using graduated placebo capsules) may be necessary before initiating therapy. Morning dosing is preferred because empagliflozin-induced glucosuria increases urine output, and daytime voiding is easier to manage than nocturia in a school-age patient [5].

Mechanism of Action in the Adolescent Context

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, preventing reabsorption of approximately 40 to 80 g of glucose per day and lowering plasma glucose independent of insulin secretion [5]. This insulin-independent mechanism is relevant to adolescents because puberty-driven insulin resistance peaks between Tanner stages 3 and 4, often making insulin-dependent therapies less effective on a per-unit basis [6].

Why SGLT2 Inhibition Fits Adolescent Physiology

Puberty increases growth hormone and IGF-1 levels, both of which antagonize insulin signaling. A medication that bypasses beta-cell demand offers a pharmacologic advantage during this window. The caloric loss from glucosuria (approximately 200 to 300 kcal/day) also contributes to weight reduction, a meaningful benefit for teens with type 2 diabetes since the majority carry a BMI above the 95th percentile [7].

Cardiorenal Effects: What Carries Over from Adult Data

In the landmark EMPA-REG OUTCOME trial (N=7,020), empagliflozin reduced cardiovascular death by 38% in adults with type 2 diabetes and established cardiovascular disease [8]. The EMPEROR-Reduced and EMPEROR-Preserved trials later demonstrated heart failure benefits independent of diabetes status [9]. These data do not directly apply to adolescents, but they inform long-term risk-benefit discussions for teens who may take the drug for decades.

Monitoring and Safety in Adolescents

Monitoring adolescents on empagliflozin requires attention to the same safety signals seen in adults, plus developmental considerations unique to this age group. The Endocrine Society Clinical Practice Guidelines recommend that clinicians screen for genital mycotic infections, volume depletion, and ketoacidosis risk at every visit [10].

Genital Mycotic Infections

SGLT2 inhibitors increase urinary glucose, creating an environment favorable to Candida overgrowth. In adult trials, genital mycotic infections occurred in roughly 5 to 10% of empagliflozin-treated women and 1 to 4% of men [4]. Adolescents may be less likely to report symptoms due to embarrassment. Proactive counseling on hygiene, symptom recognition, and early treatment with topical antifungals is essential.

Euglycemic Diabetic Ketoacidosis (DKA)

Euglycemic DKA (blood glucose <250 mg/dL with metabolic acidosis) is a rare but serious risk. The FDA issued a safety communication about SGLT2-associated ketoacidosis in 2020, recommending discontinuation before elective surgery and during acute illness [11]. Adolescents face higher DKA risk than adults because of more labile insulin requirements during growth spurts, sick-day caloric restriction, and the possibility of latent autoimmune diabetes misclassified as type 2.

Volume Depletion and Dehydration

Empagliflozin produces an osmotic diuresis. Teens involved in sports or living in hot climates need explicit hydration counseling. Baseline orthostatic vital signs and periodic electrolyte panels (sodium, potassium, bicarbonate) help identify early dehydration. The ADA recommends holding SGLT2 inhibitors during gastroenteritis or any illness that limits oral fluid intake [3].

Growth Velocity Monitoring

No signal of growth impairment emerged from DINAMO at 26 or 52 weeks [2]. Still, the caloric loss from glucosuria warrants longitudinal tracking. Clinicians should plot height velocity on CDC growth charts at 3-to-6-month intervals and reassess therapy if growth falls below the expected trajectory for Tanner stage [12].

Renal Considerations

Empagliflozin requires adequate kidney function to produce its glucosuric effect. The prescribing information sets a minimum eGFR of 30 mL/min/1.73 m² for glycemic indications. For adolescents, eGFR should be estimated using the Schwartz bedside formula rather than CKD-EPI, as CKD-EPI was validated in adults and may overestimate GFR in patients under 18 [4].

Baseline and Follow-Up Labs

Check serum creatinine, eGFR, and a urinalysis at baseline. Repeat the renal panel at 3 months after initiation, then every 6 months. An initial eGFR dip of up to 5 mL/min/1.73 m² is expected due to hemodynamic effects on the glomerulus and is not a reason to discontinue therapy [13]. The EMPA-KIDNEY trial (N=6,609) confirmed renal protective effects in adults with chronic kidney disease, showing a 28% reduction in kidney disease progression [13].

Drug Interactions Affecting Renal Function

Loop diuretics combined with empagliflozin amplify volume depletion risk. If an adolescent also takes an ACE inhibitor or ARB (sometimes prescribed for microalbuminuria in diabetes), the triple effect on intraglomerular pressure demands careful monitoring of potassium and creatinine at 1 to 2 week intervals after any dose change [4].

Comparisons with Other Pediatric Diabetes Medications

The adolescent type 2 diabetes pharmacopeia is limited. Metformin remains first-line, approved for patients aged 10 and older since 2000 [14]. Insulin (basal and prandial) is the only other universally approved option. Liraglutide gained FDA approval for ages 10+ in 2019, and exenatide extended-release for the same group in 2021 [3].

Empagliflozin vs. Metformin

Metformin produces HbA1c reductions of 1.0 to 1.5% and has a longer safety track record. Empagliflozin is not a metformin replacement but an add-on when metformin monotherapy fails to reach the ADA target of HbA1c <7% [3]. The weight reduction benefit of empagliflozin complements metformin, which is weight-neutral in most adolescent studies.

Empagliflozin vs. GLP-1 Receptor Agonists

GLP-1 receptor agonists like liraglutide produce greater weight loss (approximately 3 to 5% body weight) and larger HbA1c reductions (0.5 to 1.0%) compared with empagliflozin [3]. The trade-off: GLP-1 RAs require injection and carry higher rates of nausea and vomiting, which may reduce adherence in teenagers. Empagliflozin's once-daily oral dosing is a practical advantage for adolescents who refuse injections.

Off-Label Use and Emerging Data

While the FDA approval covers type 2 diabetes in patients aged 10+, some pediatric cardiologists have begun using empagliflozin off-label in adolescents with heart failure or cardiomyopathy, extrapolating from the EMPEROR-Reduced and EMPEROR-Preserved data in adults [15]. No randomized controlled trials have studied SGLT2 inhibitors for pediatric heart failure, and both the American Heart Association and the Endocrine Society advise that off-label pediatric use should only occur under specialist supervision with IRB-level informed consent [16].

Ongoing Trials to Watch

Several ongoing studies are expanding the evidence base. A Phase 3b open-label extension of DINAMO is tracking empagliflozin safety in adolescents beyond 52 weeks, with results expected in 2026 [2]. Separate investigator-initiated trials are examining SGLT2 inhibitors in pediatric patients with obesity-related glomerulopathy and type 1 diabetes, though neither has yet reported outcomes [4].

Practical Guidance for Families

Parents and adolescents need clear, specific instructions before starting empagliflozin. Three areas require explicit conversation.

Sick-Day Rules

Stop empagliflozin during any illness involving vomiting, diarrhea, or reduced food intake. Do not restart until the adolescent has resumed normal eating and drinking for at least 24 hours. Check blood or urine ketones if the teen feels nauseated, short of breath, or has abdominal pain, even if blood glucose appears normal [11].

School and Sports Considerations

The teen should carry a water bottle and have unrestricted bathroom access during school hours. Coaches need to know that the patient may need additional hydration breaks. For competitive athletics, hold empagliflozin the morning of events lasting longer than 90 minutes if adequate fluid intake cannot be guaranteed. The CDC physical activity guidelines for adolescents recommend 60 minutes of moderate-to-vigorous activity daily; empagliflozin does not contraindicate exercise but requires hydration planning [17].

Mental Health Screening

Adolescents with type 2 diabetes have a twofold higher prevalence of depression compared with peers without diabetes [18]. Adding a new daily medication can increase disease-related distress. Screen for diabetes distress and depressive symptoms using validated tools such as the PHQ-A at each diabetes visit, and refer to behavioral health when scores exceed threshold.

When to Discontinue or Switch

Empagliflozin should be stopped if the adolescent develops DKA, recurrent severe genital infections unresponsive to prophylaxis, or a confirmed eGFR drop below 30 mL/min/1.73 m² on two consecutive measurements [4]. If HbA1c has not improved by at least 0.3% after 12 weeks at the 25 mg dose, reassess adherence first, then consider switching to or adding a GLP-1 receptor agonist per ADA pediatric algorithm recommendations [3].

Clinicians should also hold the medication 3 to 4 days before any surgery requiring general anesthesia, given the ketoacidosis risk during perioperative fasting [11]. Resume only after the patient is eating normally and hemodynamically stable.